Cargando…

Comparative analysis of cisplatin-induced nephrotoxicity in head and neck cancer and carcinoma cervix during concurrent chemoradiotherapy

BACKGROUND: Cisplatin is widely used as radio sensitizer in head and neck cancer (HNC) and carcinoma cervix (CaCx). This study aims to see comparative nephrotoxicity of cisplatin in HNC and in CaCx without obstructive uropathy treated by concurrent chemoradiotherapy (CCRT). MATERIALS AND METHODS: Fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bagri, Puneet Kumar, Kapoor, Akhil, Kalwar, Ashok, Singhal, Mukesh Kumar, Singh, Daleep, Narayan, Satya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236700/
https://www.ncbi.nlm.nih.gov/pubmed/25422808
http://dx.doi.org/10.4103/2278-330X.142979
_version_ 1782345222072565760
author Bagri, Puneet Kumar
Kapoor, Akhil
Kalwar, Ashok
Singhal, Mukesh Kumar
Singh, Daleep
Narayan, Satya
author_facet Bagri, Puneet Kumar
Kapoor, Akhil
Kalwar, Ashok
Singhal, Mukesh Kumar
Singh, Daleep
Narayan, Satya
author_sort Bagri, Puneet Kumar
collection PubMed
description BACKGROUND: Cisplatin is widely used as radio sensitizer in head and neck cancer (HNC) and carcinoma cervix (CaCx). This study aims to see comparative nephrotoxicity of cisplatin in HNC and in CaCx without obstructive uropathy treated by concurrent chemoradiotherapy (CCRT). MATERIALS AND METHODS: Fifty patients of HNC and 50 patients of CaCx stage II/III without obstructive uropathy were included in this study. Cisplatin 50 mg intravenous weekly was given before EBRT with adequate hydration and premedication in both groups. Before chemotherapy; blood urea, serum creatinine, and glomerular filtration rate (GFR) were measured. GFR was measured using (99m)Tc diethylene triamine pentacaetic acid (DTPA) renogram study. RESULTS: At the end of 4(th) week, blood urea level 41-45 mg% was in 40 and 4% in HNC and CaCx, respectively (P = 0.018). At the end of 3(rd) and 4(th) week, blood urea level >45 mg% was 10 and 6% in HNC cases, respectively. At the end of 4(th) week, serum creatinine level 1.1-1.5 mg% was 50 and 8% in HNC and CaCx, respectively (P = 0.047). Serum creatinine level >1.5 mg% was 6, 8, and 22% in HNC at the end of 2(nd), 3(rd), and 4(th) week, respectively. GFR <80 ml/min at the end of 4(th) week was 14% in HNC and only 2% in CaCx. GFR <100ml/min was significant at the end of 4(th) week (P = 0.04). Univariate analysis showed significant relation between reduced oral fluid intake and reduced GFR (P < 0.001). CONCLUSION: In HNC, during concurrent chemoradiation, as the 3(rd)-4(th) week is reached, oral mucosal reactions increase and affect oral intake which further add to the cisplatin-induced nephrotoxicity. In CaCx without obstructive uropathy, renal function impairment is less severe as oral intake of water and liquid is not much impaired.
format Online
Article
Text
id pubmed-4236700
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-42367002014-11-24 Comparative analysis of cisplatin-induced nephrotoxicity in head and neck cancer and carcinoma cervix during concurrent chemoradiotherapy Bagri, Puneet Kumar Kapoor, Akhil Kalwar, Ashok Singhal, Mukesh Kumar Singh, Daleep Narayan, Satya South Asian J Cancer TREATMENT TOXICITY BACKGROUND: Cisplatin is widely used as radio sensitizer in head and neck cancer (HNC) and carcinoma cervix (CaCx). This study aims to see comparative nephrotoxicity of cisplatin in HNC and in CaCx without obstructive uropathy treated by concurrent chemoradiotherapy (CCRT). MATERIALS AND METHODS: Fifty patients of HNC and 50 patients of CaCx stage II/III without obstructive uropathy were included in this study. Cisplatin 50 mg intravenous weekly was given before EBRT with adequate hydration and premedication in both groups. Before chemotherapy; blood urea, serum creatinine, and glomerular filtration rate (GFR) were measured. GFR was measured using (99m)Tc diethylene triamine pentacaetic acid (DTPA) renogram study. RESULTS: At the end of 4(th) week, blood urea level 41-45 mg% was in 40 and 4% in HNC and CaCx, respectively (P = 0.018). At the end of 3(rd) and 4(th) week, blood urea level >45 mg% was 10 and 6% in HNC cases, respectively. At the end of 4(th) week, serum creatinine level 1.1-1.5 mg% was 50 and 8% in HNC and CaCx, respectively (P = 0.047). Serum creatinine level >1.5 mg% was 6, 8, and 22% in HNC at the end of 2(nd), 3(rd), and 4(th) week, respectively. GFR <80 ml/min at the end of 4(th) week was 14% in HNC and only 2% in CaCx. GFR <100ml/min was significant at the end of 4(th) week (P = 0.04). Univariate analysis showed significant relation between reduced oral fluid intake and reduced GFR (P < 0.001). CONCLUSION: In HNC, during concurrent chemoradiation, as the 3(rd)-4(th) week is reached, oral mucosal reactions increase and affect oral intake which further add to the cisplatin-induced nephrotoxicity. In CaCx without obstructive uropathy, renal function impairment is less severe as oral intake of water and liquid is not much impaired. Medknow Publications & Media Pvt Ltd 2014 /pmc/articles/PMC4236700/ /pubmed/25422808 http://dx.doi.org/10.4103/2278-330X.142979 Text en Copyright: © South Asian Journal of Cancer http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle TREATMENT TOXICITY
Bagri, Puneet Kumar
Kapoor, Akhil
Kalwar, Ashok
Singhal, Mukesh Kumar
Singh, Daleep
Narayan, Satya
Comparative analysis of cisplatin-induced nephrotoxicity in head and neck cancer and carcinoma cervix during concurrent chemoradiotherapy
title Comparative analysis of cisplatin-induced nephrotoxicity in head and neck cancer and carcinoma cervix during concurrent chemoradiotherapy
title_full Comparative analysis of cisplatin-induced nephrotoxicity in head and neck cancer and carcinoma cervix during concurrent chemoradiotherapy
title_fullStr Comparative analysis of cisplatin-induced nephrotoxicity in head and neck cancer and carcinoma cervix during concurrent chemoradiotherapy
title_full_unstemmed Comparative analysis of cisplatin-induced nephrotoxicity in head and neck cancer and carcinoma cervix during concurrent chemoradiotherapy
title_short Comparative analysis of cisplatin-induced nephrotoxicity in head and neck cancer and carcinoma cervix during concurrent chemoradiotherapy
title_sort comparative analysis of cisplatin-induced nephrotoxicity in head and neck cancer and carcinoma cervix during concurrent chemoradiotherapy
topic TREATMENT TOXICITY
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236700/
https://www.ncbi.nlm.nih.gov/pubmed/25422808
http://dx.doi.org/10.4103/2278-330X.142979
work_keys_str_mv AT bagripuneetkumar comparativeanalysisofcisplatininducednephrotoxicityinheadandneckcancerandcarcinomacervixduringconcurrentchemoradiotherapy
AT kapoorakhil comparativeanalysisofcisplatininducednephrotoxicityinheadandneckcancerandcarcinomacervixduringconcurrentchemoradiotherapy
AT kalwarashok comparativeanalysisofcisplatininducednephrotoxicityinheadandneckcancerandcarcinomacervixduringconcurrentchemoradiotherapy
AT singhalmukeshkumar comparativeanalysisofcisplatininducednephrotoxicityinheadandneckcancerandcarcinomacervixduringconcurrentchemoradiotherapy
AT singhdaleep comparativeanalysisofcisplatininducednephrotoxicityinheadandneckcancerandcarcinomacervixduringconcurrentchemoradiotherapy
AT narayansatya comparativeanalysisofcisplatininducednephrotoxicityinheadandneckcancerandcarcinomacervixduringconcurrentchemoradiotherapy